10-Q: Semnur Pharmaceuticals Faces Liquidity Crisis, Terminates Key Financing

Semnur Pharmaceuticals reported increased losses and negative cash flow for Q1 2026, raising substantial doubt about its going concern ability, while terminating two significant equity financing agreements.

Summary

• Net loss for the three months ended March 31, 2026, was $4.6 million, a significant increase from $0.7 million for the same period in 2025.
• Operating expenses surged to $4.6 million in Q1 2026 from $0.7 million in Q1 2025, primarily driven by higher research and development ($1.3 million vs. $0.2 million) and general and administrative costs ($3.3 million vs. $0.5 million).
• Cash and cash equivalents stood at a critically low $0.1 million as of March 31, 2026, with an accumulated deficit of $280.4 million.
• Negative cash flow from operations worsened to $2.7 million for Q1 2026, compared to $0.4 million for Q1 2025.
• Two significant equity financing agreements, the PIPE SPA ($20.0 million) and the Semnur/Biconomy SPA ($100.0 million, payable in Bitcoin), were terminated on April 20, 2026, removing $120.0 million in potential capital.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least one year after the issuance date of the financial statements.
• The company is dependent upon Scilex Holding Company for services and funding to support its operations until external financing is obtained.
• A second Phase 3 study for its lead product candidate, SP-102, was initiated in September 2025, following FDA guidance for a confirmatory trial with a larger safety database and evidence of efficacy through repeat injection.
• The company failed to make certain scheduled installment payments during Q1 2026 on promissory notes totaling $2.7 million, but expects to make these payments in June 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with significant negative sentiment due to substantially increased losses, worsening cash burn, explicit 'going concern' doubt, and the termination of two major financing agreements, indicating severe liquidity challenges despite ongoing clinical trials.

Positives

• The lead product candidate, SP-102, has completed a pivotal Phase 3 study with results reflecting achievement of primary and secondary endpoints, showing decreased pain intensity and improved disability index for sciatica patients.
• SP-102 has been granted fast track designation by the FDA, which could potentially lead to a faster development or regulatory review process.
• A second Phase 3 study for SP-102 was initiated in September 2025, demonstrating continued progress in clinical development.
• Cash and cash equivalents increased to $0.1 million at March 31, 2026, from $0.02 million at December 31, 2025, primarily due to financing activities.
• Net cash provided by financing activities increased to $2.753 million for Q1 2026, up from $0.394 million for Q1 2025.

Negatives

• Net loss significantly increased to $4.6 million for the three months ended March 31, 2026, from $0.7 million in the prior year period.
• Accumulated deficit grew to $280.4 million as of March 31, 2026, indicating substantial historical losses.
• Negative cash flow from operations worsened to $2.7 million for the three months ended March 31, 2026, from $0.4 million in the prior year period, highlighting increased cash burn.
• Two major financing agreements, the PIPE SPA ($20.0 million) and the Semnur/Biconomy SPA ($100.0 million), were terminated in April 2026, removing significant potential capital.
• The company failed to make certain scheduled installment payments on promissory notes during Q1 2026, indicating immediate liquidity strain.
• Management explicitly stated 'substantial doubt about the Company’s ability to continue as a going concern' for one year after the financial statements' issuance date.
• Research and development expenses increased significantly to $1.3 million in Q1 2026 from $0.2 million in Q1 2025, reflecting increased costs without corresponding revenue.
• General and administrative expenses increased significantly to $3.3 million in Q1 2026 from $0.5 million in Q1 2025, partly due to public company operating costs.
• The FDA did not agree that the clinical data from the single CLEAR-1 trial was sufficient for SP-102's 505(b)(2) NDA submission, requiring a confirmatory trial, which extends the development timeline.
• Identified material weaknesses in internal control over financial reporting related to carve-out financial statements and stock-based compensation expense for years ended December 31, 2023 and 2022.

Risks

• The company is a late-stage clinical specialty pharmaceutical company with a limited operating history, significant accumulated losses ($280.4 million), and anticipates continued losses for the foreseeable future.
• It has only one product candidate (SP-102), no products approved for commercial sale, has never generated revenue from product sales, and may never be profitable.
• Recurring losses from operations, negative cash flows, and substantial cumulative net losses raise substantial doubt about the company's ability to continue as a going concern.
• The company historically obtained its clinical supply of SP-102 and certain raw materials from sole or single-source suppliers (e.g., Lifecore Biomedical, LLC), posing risks of supply disruption or regulatory non-compliance.
• Reliance on third parties to conduct clinical trials introduces risks of contractual non-compliance, failure to meet deadlines, or inability to obtain regulatory approvals.
• Delays in clinical trials could result in increased costs and delay the ability to obtain commercial approval and generate revenue.
• Regulatory approval processes are time-consuming and unpredictable; approval in one jurisdiction does not ensure approval in others, limiting total market potential.
• The FDA did not conclude that SP-102 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway based on the initial Phase 3 trial, requiring a confirmatory trial, which will likely take longer and cost more.
• Any approved product candidate will be subject to ongoing and continued regulatory requirements, resulting in significant expense and potential limitations on commercialization.
• The company currently has no sales and marketing organization and may not successfully commercialize SP-102 or any future product candidates if it cannot establish satisfactory capabilities or third-party relationships.
• Inability to retain key executives (Henry Ji, Stephen Ma) may delay development efforts and harm the business.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization of product candidates.
• Disruptions in research and development facilities (e.g., natural disasters, cybersecurity attacks) could adversely affect business.
• Inability to maintain patent protection for product candidates or insufficient scope of protection could impair competitive advantage.
• Intellectual property rights may be invalidated or circumvented, adversely affecting the business.
• Confidentiality agreements with employees may not adequately prevent disclosure of trade secrets and proprietary information.
• The company may become subject to claims challenging the inventorship or ownership of its patents and other intellectual property.
• Claims of infringement, misappropriation, or violation of third-party intellectual property rights may lead to costly litigation and prevent product sales.
• Healthcare reform measures could hinder or prevent product candidates' commercial success by impacting pricing and reimbursement.
• The company is subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, and sanctions laws.
• Certain directors and officers have actual or potential conflicts of interest due to their positions with Scilex Holding Company.
• The company is controlled by Scilex, whose interests may differ from those of public shareholders, and Scilex, as a holder of Series A Preferred Stock, has preferential rights.
• The company's cryptocurrency treasury strategy (though the primary funding source was terminated) has not been implemented or tested, and the price of Bitcoin is highly volatile, posing risks to financial position.
• If digital assets held are classified as securities, the company may be subject to extensive regulation, resulting in significant costs or forced cessation of operations.
• The lack of legal recourse and insurance for digital assets increases the risk of total loss in the event of theft or destruction.

Future Outlook

Semnur Pharmaceuticals expects to incur significant expenses and operating losses for the foreseeable future as it continues its efforts to develop and seek regulatory approval for SP-102. The company will need additional financing to fund its ongoing activities and is currently exploring various financing alternatives, including new credit facilities, non-dilutive options such as collaborations and royalty financings, and equity financing options like standby equity purchase arrangements or private placements. The company's plans are dependent on the success of future development and regulatory approval of SP-102, and successful completion of financing plans is subject to factors outside its control.

Management Comments

• "We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients lives."
• "Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions."
• "Through rigorous research and development, we believe we are on the cusp of establishing Semnur as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies."
• "We believe that we have made substantial progress in demonstrating the rapid onset and enhanced tolerability of our product candidate."
• "We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned research and development activities."
• "Management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the condensed consolidated financial statements are issued."

Industry Context

StockSavvy.ai notes that Semnur Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting the non-opioid pain management market. The company's focus on SP-102 for sciatica, a condition with no FDA-approved epidural steroid products, presents a unique market opportunity. However, the industry is dominated by larger players with greater resources, and the regulatory pathway for novel therapies is lengthy and uncertain. The termination of significant financing agreements highlights the severe challenges faced by smaller, late-stage clinical companies in securing funding, especially when confronting increased R&D costs and an explicit 'going concern' warning. The company's previous delisting from Nasdaq and current OTCQB trading also reflects challenges in maintaining public market visibility and investor confidence compared to more established industry participants.

Comparison to Industry Standards

• Semnur's accumulated deficit of $280.4 million and recurring operating losses are common for late-stage biopharmaceutical companies prior to product commercialization, but the magnitude, coupled with minimal cash reserves ($0.1 million), is critically low compared to peers with stronger cash positions or more diverse pipelines.
• The FDA's requirement for a second confirmatory Phase 3 trial for SP-102, despite positive initial Phase 3 results, indicates a higher bar for approval in the non-opioid pain space, potentially due to the risks associated with interventional procedures. This requirement will extend development timelines and costs beyond what might be expected for a 505(b)(2) pathway, which is a significant hurdle compared to companies with clearer regulatory paths.
• The termination of two significant capital raise agreements (PIPE SPA for $20.0 million and Semnur/Biconomy SPA for $100.0 million) is a severe setback, contrasting sharply with successful financing rounds often seen in the biotech sector for companies with late-stage assets. This suggests significant challenges in attracting and retaining investor confidence, potentially due to market perception of its product or financial health.
• The identified material weaknesses in internal control over financial reporting, particularly concerning carve-out financial statements and stock-based compensation, are below industry best practices for public companies and could signal governance issues that deter institutional investors, unlike more mature biotech firms.
• The reliance on Scilex Holding Company for funding and services, including a Transition Services Agreement capped at $2.0 million annually, indicates a lack of standalone operational maturity and financial independence, which is atypical for a company seeking to commercialize a lead product candidate without a robust independent funding strategy.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• The Legacy Semnur Merger Agreement includes contingent cash consideration of up to $280.0 million based on FDA approval and net sales milestones, which are expected to be charged back to Semnur. None of these payments have been triggered to date.
• The Shah Assignment Agreement requires royalty payments (1.5% up to $250.0 million annual net sales, 2.5% above) for intellectual property related to corticosteroid pharmaceutical compositions. None of these payments have been triggered to date.
• The company was previously a Guarantor under a Subsidiary Guarantee for Scilex's $101.9 million Scilex-Oramed Note but is no longer a Guarantor as of September 22, 2025, following the Business Combination.

Related Party Transactions

• Loans from Scilex Holding Company totaled $4.987 million for the three months ended March 31, 2026, including $1.484 million for stock-based compensation and $3.503 million for expenses paid by Scilex on behalf of the company. These are reflected as related party loans ($16.915 million as of March 31, 2026) and do not carry interest.
• Pursuant to the Debt Exchange Agreement, outstanding indebtedness between the company and Scilex totaling $54.2 million was converted into 5,423,606 shares of Series A Preferred Stock and 542,361 shares of Common Stock at the Business Combination closing.
• The company entered into a Transition Services Agreement with Scilex on September 22, 2025, for three years, where Scilex provides various business functions (finance, HR, IT, legal, R&D, commercialization support) on a cost plus 10% basis, not exceeding $2.0 million per annum until the Scilex-Oramed Note is paid. Accrued service fees of $0.38 million were recorded as of March 31, 2026.
• Scilex Holding Company controls approximately 81.9% of the company's voting power and holds Series A Preferred Stock with preferential rights, including the right to designate directors and consent rights over certain corporate actions.
• Henry Ji, Ph.D. (CEO & President, Executive Chairman) and Stephen Ma (CFO, COO, SVP & Secretary) also hold executive positions at Scilex, creating potential conflicts of interest.

Stakeholder Impact

• Shareholders face significant dilution risk from any future capital raises, potential loss of investment due to the explicit 'going concern' doubt, and reduced influence due to Scilex's controlling ownership and preferential rights of Series A Preferred Stock. The termination of major financing deals negatively impacts future growth prospects and share price.
• Employees face uncertainty due to the company's 'going concern' status and reliance on Scilex for operational support. Future hiring plans are dependent on securing additional financing.
• Creditors, particularly holders of promissory notes, face payment delays, as the company failed to make certain scheduled payments in Q1 2026. The 'going concern' doubt increases credit risk for all creditors.
• Future customers for SP-102 may face delays in product availability due to extended clinical trial requirements and significant funding challenges, impacting patient access to a potential non-opioid pain management solution.
• Suppliers and partners, such as Lifecore Biomedical, LLC, face risks related to the company's financial stability and ability to fund manufacturing activities and other contractual obligations. Other third-party contractors also face payment risks.
• Scilex Holding Company, as the controlling shareholder and primary financier, bears significant financial risk related to Semnur's 'going concern' status and continued operational support. While its preferential rights as a Series A Preferred Stock holder provide some protection, its investment is still exposed to Semnur's financial distress.

Next Steps

• Continue efforts to develop and seek regulatory approval for SP-102, including conducting the confirmatory CLEAR-2 Phase 3 trial as requested by the FDA.
• Obtain additional funding through various financing alternatives, such as equity offerings, debt financings, collaborations, government contracts, or other capital sources, to address liquidity concerns and fund operations.
• Engage and increase full-time employees to support research and development, general administrative, manufacturing, regulatory, and commercial functions as the company enters the final stage of development and pre-launch commercialization planning.
• Implement and improve operational, financial, and management systems, including potentially an enterprise resource planning (ERP) system, to enhance efficiency and control.
• Remediate identified material weaknesses in internal control over financial reporting related to carve-out financial statements and stock-based compensation expense.
• Make missed promissory note payments in June 2026 to avoid further defaults and potential acceleration of debt.
• Potentially apply for a specific J-Code for SP-102 if it receives regulatory approval, to facilitate reimbursement.

Key Dates

Recommendation

The filing presents a dire financial situation for Semnur Pharmaceuticals. The company reported a substantial increase in net loss and negative cash flow from operations, coupled with a critically low cash balance of $0.1 million and an accumulated deficit of $280.4 million. Management explicitly raised 'substantial doubt about the Company’s ability to continue as a going concern.' Furthermore, the termination of two significant financing agreements, totaling $120.0 million, removes crucial capital needed for operations and clinical development. The requirement for an additional confirmatory Phase 3 trial for SP-102 by the FDA will extend development timelines and increase costs, further exacerbating liquidity issues. The failure to make scheduled promissory note payments and identified material weaknesses in internal controls underscore severe operational and financial instability. Given these compounding negative factors and the high risk of insolvency, a strong sell recommendation is warranted.

Keywords

Semnur Pharmaceuticals, SP-102, SEMDEXA, Biopharmaceutical, Non-opioid pain management, Sciatica, Phase 3 clinical trial, SEC filing, 10-Q, Financial results, Going concern, Liquidity, Capital raise, Clinical development, FDA fast track, Corporate governance, Risk factors, Intellectual property, Cryptocurrency strategy, Scilex Holding Company, OTCQB, SMNR